Sign In
Buy ADCT
$1.15
+0.0600 (+5.50%)
At Close: Jun 23, 2026
Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patient
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
07:00am, Wednesday, 03'rd Apr 2024
LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024, from
ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript
01:24pm, Wednesday, 13'th Mar 2024
ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
09:21am, Wednesday, 13'th Mar 2024
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.30 per share a year ago.
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
07:00am, Wednesday, 13'th Mar 2024
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settings
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
07:15am, Wednesday, 06'th Mar 2024
LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggen
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
07:00am, Wednesday, 06'th Mar 2024
LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024, at 8:30 a.
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
05:45pm, Tuesday, 05'th Mar 2024
Preclinical data support future clinical development of ADCs targeting Claudin-6 and NaPi2b Additional presentations include clinical and independent preclinical studies evaluating ADCT-601 targeting
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
07:00am, Tuesday, 27'th Feb 2024
LAUSANNE, Switzerland, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the TD Cowen 44
Earnings Preview: ADC Therapeutics SA (ADCT) Q4 Earnings Expected to Decline
11:06am, Tuesday, 20'th Feb 2024
ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The 3 Biotech Stocks That Could Make Your February Unforgettable
11:57am, Thursday, 15'th Feb 2024
Following a hot year of M&A with biotech stocks, we'll see more of the same in 2024 as drug makers look to build their pipelines ahead of a massive patent cliff. Between now and 2028, pharmaceutical g
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
01:15pm, Thursday, 08'th Feb 2024
With patience, some of the most undervalued biotech stocks can create massive wealth. Look at ACADIA Pharmaceuticals (NASDAQ: ACAD ), for example.
The Jobs Report Blows Away Forecasts
09:26pm, Friday, 02'nd Feb 2024
January's payrolls report shows 353,000 jobs
ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why
02:06pm, Friday, 19'th Jan 2024
ADC Therapeutics (ADCT) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
10:41am, Friday, 19'th Jan 2024
Here is how ADC Therapeutics SA (ADCT) and CytomX Therapeutics (CTMX) have performed compared to their sector so far this year.
